Document is current

Article History

Received: 30 January 2024

Accepted: 30 December 2024

First Online: 21 January 2025

Declarations

:

: The study protocol and questionnaire for the NHWS were reviewed by the Pearl Institutional Review Board and were granted an exemption from review. Potential respondents were invited to complete the survey via an email invitation. Respondents who clicked the email link from their invitation were then directed to an informed consent statement and, if they provided consent, were provided screening questions to assess eligibility.

: Not applicable.

: JB, ARM, AJ, and KHB are employees of Pfizer, Inc. SD and NS are employees of Oracle Life Sciences, which was a paid consultant to Pfizer to conduct the study and to develop the manuscript. ARM was an employee of Oracle Life Sciences at the time of this study. AG reports financial support for ad boards, consulting and speaker honoraria from: Grünenthal, Mundipharma, Abbvie/Allergan, Lilly, Teva, Amgen, Novartis, Hormosan, Stada, Lundbeck, Pfizer, Hexal, Esanumperfood, Medscape, streamed up, Ärztekammer Nordrhein, Ärztekammer Westfalen Lippe, DGS, Regionalbeauftragte der DMKG. GC has received honoraria for participation in clinical trials and contribution to advisory boards or presentations from TEVA, Biohaven, Eli Lilly, Abbvie, and Pfizer. He serves as an Associate Editor for Cephalalgia, BMC Neurology – Pain section, Frontiers in Neurology – Neurotechnology section, Frontiers in Human Neuroscience – Brain Imaging and Stimulation section, and on the Advisory Board of The Journal of Headache and Pain.